Over half a million people die from cancer every year, according to current statistics. For those diagnosed with pancreatic cancer, the current five-year survival rate is 12% but for those diagnosed in metastatic stages, survival is less than 3%. A startup leveraging technology created at the University of Tennessee Health Science Center (UTHSC) is now (read more)
Inventions & Patents
Long-term vision and partnership: UTRF startup to develop next-generation RNA medicines using a novel drug delivery system
Around a decade ago, a researcher at the University of Tennessee Graduate School of Medicine (UTSGM) and a graduate student in her lab began to imagine creating a company based on a technology they were developing. In 2022, their initial dream became a reality. They launched Orion Therapeutics, a biotechnology startup company developing next-generation RNA (read more)
UTRF Licensee Veru, Inc. Announces Positive Results of COVID-19 Therapy’s Phase 3 Clinical Study, Seeking Emergency Use Authorization from FDA
UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)